Pyxis Oncology
PYXS
45 hedge funds and large institutions have $76.1M invested in Pyxis Oncology in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 11 closing their positions.
1.86% more ownership
Funds ownership: 55.98% → 57.83% (+1.9%)
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
12% less funds holding
Funds holding: 51 → 45 (-6)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
62% less capital invested
Capital invested by funds: $200M → $76.1M (-$124M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.83M |
| 2 |
Barclays
London,
United Kingdom
|
+$6.94M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$4.19M |
| 4 |
Citigroup
New York
|
+$1.68M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$420K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.39M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.49M |
| 3 |
DM
Deerfield Management
New York
|
-$3.42M |
| 4 |
PA
Perceptive Advisors
New York
|
-$3.04M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$2.74M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCM
51
Ghisallo Capital Management
Boston,
Massachusetts
| – | -$329K | -30,000 | Closed |
|
52
Walleye Capital
New York
| – | -$175K | -15,933 | Closed |
|
53
D.E. Shaw & Co
New York
| – | -$114K | -10,367 | Closed |
|
54
Millennium Management
New York
| – | -$112K | -10,253 | Closed |
|
|
DKCM
55
Davidson Kempner Capital Management
New York
| – | -$109K | -10,000 | Closed |
|
|
SIM
56
Sandia Investment Management
Boston,
Massachusetts
| – | -$110K | -10,000 | Closed |
|
PYXS Hedge Fund Activity: Q1 2022 in Review
45 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q1 2022, worth a combined $76.1M — down 62% from $200M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PYXS and 5 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 14 added.
The largest buyer was BVF Inc, adding an estimated $7.83M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.39M sold.
- 45 institutional investors held Pyxis Oncology (PYXS) as of Q1 2022, down from 51 in Q4 2021.
- Funds reported $76.1M of Pyxis Oncology stock for Q1 2022, down 62% quarter-over-quarter.
- 5 funds opened new Pyxis Oncology positions in Q1 2022 and 11 closed out, a net change of -6 holders.
- The largest Pyxis Oncology buyer in Q1 2022 was BVF Inc, an estimated $7.83M added.
- The largest Pyxis Oncology seller in Q1 2022 was Great Point Partners, an estimated $4.39M sold.
Based on aggregated 13F filings for Q1 2022.